Cajeta, Rowena M.
HRN: 18-45-91 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
12/17/2022
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
12/17/2022
12/18/2022
IVT
500mg
Q8 X 3 Doses
S/P Primary LTCS
Waiting Final Action
Indication: Prophylaxis Type of Infection: Reproductive Tract Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes